Article

Comparable Outcomes Using Low-Dose Apixaban and Anti-Xa Monitoring and Vitamin-K Antagonists in Patients with Renal Replacement Therapy

2026-05-12

Abstract excerpt

Background: Guidelines recommend the use of oral anticoagulation for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism. Outside the USA, apixaban is contraindicated for use in patients with end stage renal disease (ESRD) receiving renal replacement therapy (RRT). Aim: To compare thrombotic and safety outcomes in patients receiving either vitamin...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: f32523a8-3c1a-5974-b185-42a6c8f9b2c7
DOI: 10.22541/authorea.15003089/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Comparable Outcomes Using Low-Dose Apixaban and Anti-Xa Monitoring and Vitamin-K Antagonists in Patients with Renal Replacement TherapyDOI 10.22541/authorea.15003089/v1Read

Safety profile of rivaroxaban in first-time users treated for venous thromboembolism (deep vein thrombosis and pulmonary embolism) in four European countriesSemantic proximity Read

Effectiveness and Safety of Anticoagulants Among Patients with Venous Thromboembolism and Active Cancer Who Also Had Prior Bleed or Prior Renal DiseaseSemantic proximity Read

Real-world experience: Effect of Apixaban on INR, More confusion to providers with inadvertent labSemantic proximity Read

Thrombosis and Bleeding Risk in Chronic Kidney Disease: Hematologic Alterations, Pathophysiology, and Management StrategiesSemantic proximity Read

[Anticoagulation with warfarin].Semantic proximity Read

The impact of ABCB1, CYP3A4 and CYP3A5 gene polymorphisms on apixaban trough concentration and bleeding risk in patients with atrial fibrillation.Semantic proximity Read

Population pharmacokinetics and hemorrhagic risk analysis of rivaroxaban in Chinese elderly patients with non-valvular atrial fibrillationSemantic proximity Read

Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia.Semantic proximity Read

Gastrointestinal Bleeding During Direct Oral Anticoagulants Therapy in Patients With Nonvalvular Atrial Fibrillation and Risk of PolypharmacySemantic proximity Read

Medication review with follow-up service by community pharmacists forpatients under treatment with coumarin anticoagulants in collaboration with Primary CareSemantic proximity Read

Interindividual Variability of Apixaban Plasma Concentrations: Influence of Clinical and Genetic Factors in a Real-Life Cohort of Atrial Fibrillation Patients.Semantic proximity Read

Ex-vivo antiplatelet effects of oral anticoagulantsSemantic proximity Read